InnovAge Holding Corp. (INNV) stock intrinsic value fair value estimate & owner earnings analysis

InnovAge is the largest provider of PACE (Program of All-Inclusive Care for the Elderly) in the United States, serving about 8,230 frail, mostly dual-eligible seniors at June 30, 2026 (up from about 7,740 a year earlier) through 20 centers in Colorado, California, New Mexico, Pennsylvania, Virginia and Florida. It is paid a fixed monthly amount per participant (56% of capitation revenue from Medicaid, 44% from Medicare in fiscal 2026) and in return is responsible for all of that person's medical care, from day-center services and home care to hospital, nursing-home and pharmacy costs. Profit is the thin gap between those capitation rates and the cost of care, so small moves in state Medicaid rates, nursing-facility use or regulatory standing swing results sharply. Its largest group of participants is in Colorado. Earnings record. We measure owner earnings as operating cash flow, less swings in working capital, stock compensation and the capital spending needed to keep the centers running. To value the business before its lenders, we add back cash interest and charge its finance-lease payments (about $6 million a year recently). On that basis the business produced about $47.5 million in fiscal 2020, then lost money every year from fiscal 2021 through 2025. Fiscal 2021 carried fees from the 2020 Apax transaction and the March 2021 IPO. The later years include regulatory sanctions that restricted new enrollment at its Sacramento and Colorado centers (their release lifted enrollment in fiscal 2024), de novo centers abandoned in Louisville, Kentucky and Downey, California, and investments during fiscal 2025 and 2026 to strengthen its capabilities as a payor. Fiscal 2026 marked a clear turn: revenue rose 15.9% to $989.7 million on 7.8% more member months and a 7.6% rise in capitation rates, external provider cost per participant fell 3.2% (less nursing-facility use and a move to in-house pharmacy), and the net loss narrowed to $0.7 million from $35.3 million. Key accounting judgement. Fiscal 2026 includes a $36.8 million increase in litigation expense, mainly the accrual for settling the Colorado Attorney General's 2021 and the Department of Justice's 2022 False Claims Act investigations into billing and quality of care. The company had $37.0 million accrued at June 30, 2026 and says it does not expect a material loss beyond that. We treat this as a one-time cost: we leave it out of recurring earnings and instead subtract the full $37.0 million as money owed. Adjusted this way, and after removing interest income on cash that we count separately, fiscal 2026 business cash flow was about $50 million. Asset impairments are non-cash and are added back. Starting level. We see only two years that were not distorted, fiscal 2020 (about $47.5 million) and fiscal 2026 (about $50 million), so we place normal earning power near $49 million. Fiscal 2021 was distorted by transaction costs, and fiscal 2022-2025 by the sanctions and their aftermath, which do not describe today's larger footprint now that those sanctions have been released. The fiscal 2026 improvement was not a single good quarter: the company was profitable in the first half and again in the fourth quarter, even after adding to the litigation accrual. Earnings did turn in the most recent year, from a loss to a gain, so no meaningful growth rate exists to compare against. Every case starts year one at or below the fiscal 2026 level because of named headwinds in the filing. The company expects a cut in Colorado Medicaid rates, backdated to July 1, 2026. It expects Medicaid wage-rate pressure from states such as California resetting rates on January 1, 2027. And the federal Reconciliation Act limits how states can use provider taxes to fund Medicaid. The size of the Colorado cut is not disclosed. Part of fiscal 2026's rate gain also came from a lower revenue reserve, an amount the filing does not quantify. Base case ($4.29 per share). The fiscal 2026 gains partly reverse: we take about $14 million off the $50 million level for the Colorado cut, California wage pressure and continuing regulatory work, such as the corrective action plan California issued on December 23, 2025 for the San Bernardino center. That leaves $36 million a year with no growth credited, which gives a business value of about $600 million. With net obligations of about $18 million, equity is worth about $582 million, or $4.29 per share. Bear case ($1.13 per share). The rate cuts wipe out the fiscal 2026 improvement, taking fiscal 2027 back to the roughly break-even cash flow of fiscal 2024-2025 (minus $5 million). In fiscal 2028-2029 a fresh enrollment restriction hits a major market, costing $20 million a year. The evidence for that risk is the company's sanction history, the open San Bernardino corrective action plan, and California's pause on new PACE center applications, in effect since November 20, 2025. The fiscal 2023 sanction year was worse, at about minus $59 million. After that, cash flow settles at $15 million a year, roughly what fiscal 2026 produced even with the litigation charge. The business is worth about $171 million; less $18 million owed, equity is worth about $153 million, or $1.13 per share. The term loan matures August 8, 2028. In this case, cash left after the settlement and these losses (about $59 million) would still exceed the loan balance, though with little cushion. Bull case ($7.13 per share). The lower nursing-facility use and in-house pharmacy savings that drove fiscal 2026 fully offset the rate cuts, holding $50 million in fiscal 2027. Census then grows about 4% a year for five years, below the 6.3% gain of fiscal 2026, by filling existing centers, including the Tampa joint venture with Tampa General Hospital added in August 2025, and then holds flat at about $61 million. The business is worth about $985 million; less $18 million owed, about $967 million, or $7.13 per share. In every case we credit nothing beyond year ten except keeping the level reached. InnovAge is the largest operator in an established Medicare and Medicaid program, runs 20 centers (10 owned), and relies on ongoing enrollment to replace participants, whose average tenure is about three years. New de novo centers are left out: the Downey application was withdrawn in July 2026, and Bakersfield depends on California restoring its attestation. Acquisitions are also left out. Debt and obligations. Net obligations of about $18 million are made up of the $48.8 million term loan (6.15%, close enough to our 6% rate to need no adjustment), the $37.0 million litigation accrual, and about $33 million for outside partners' share of its Sacramento, Orlando and Tampa joint ventures (including $30.0 million of redeemable interests at fair value). Against these we count about $101 million of the $141.3 million in cash and short-term investments, holding back $40 million to run the business. The $100 million revolver was undrawn at June 30, 2026, apart from letters of credit. Finance-lease balances (about $14.5 million) are not subtracted separately because their ongoing payments are already charged in each case. What would make this wrong: a DOJ settlement well above the accrual; a Colorado Medicaid cut deep enough to push margins back to fiscal 2024-2025 levels; or new sanctions at a large center. On the upside, a sustained fiscal 2026 margin would support the bull case. The margin-of-safety price is $2.25. That is a wide discount to the base case, because the bear case sits far below it and results depend heavily on state rate decisions and regulators.